(Q29394405)

14 April 2017

author name string

Stefan Esser

1

1 reference

14 April 2017

Doris Helbig

2

1 reference

14 April 2017

Uwe Hillen

3

1 reference

14 April 2017

Joachim Dissemond

4

1 reference

14 April 2017

Stephan Grabbe

5

1 reference

14 April 2017

publication date

September 2007

1 reference

14 April 2017

1 reference

14 April 2017

volume

5

1 reference

14 April 2017

page(s)

745-754

1 reference

14 April 2017

issue

9

1 reference

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

14 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Fat distribution in men with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Liposuction for protease-inhibitor-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Severe cutaneous reactions associated with the use of human immunodeficiency virus medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Cutaneous manifestations of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Incidence and risk factors for nevirapine-associated rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Indinavir-induced retinoid-like effects: incidence, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

Emtricitabine (FTC) for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06322.X

10.1111/J.1610-0387.2007.06322.X

21 January 2018

Identifiers

DOI

1 reference